advertisement

Topcon

Ishida K 8

Showing records 1 to 8 | Display all abstracts from Ishida K

90701 One-Year Efficacy and Safety Assessment of Ripasudil, a Rho Kinase Inhibitor, in an Addition to or Replacing Existing Treatment Regimens: A Retrospective Study
Tsukahara S
Journal of Ocular Pharmacology and Therapeutics 2020; 36: 512-521
90766 Evaluation of bleb characteristics after trabeculectomy and glaucoma implant surgery in rabbit
Ishida K
Ophthalmic Research 2021; 64: 68-76
90701 One-Year Efficacy and Safety Assessment of Ripasudil, a Rho Kinase Inhibitor, in an Addition to or Replacing Existing Treatment Regimens: A Retrospective Study
Enomoto N
Journal of Ocular Pharmacology and Therapeutics 2020; 36: 512-521
90766 Evaluation of bleb characteristics after trabeculectomy and glaucoma implant surgery in rabbit
Nakano Y; Ojino K
Ophthalmic Research 2021; 64: 68-76
90701 One-Year Efficacy and Safety Assessment of Ripasudil, a Rho Kinase Inhibitor, in an Addition to or Replacing Existing Treatment Regimens: A Retrospective Study
Ishida K
Journal of Ocular Pharmacology and Therapeutics 2020; 36: 512-521
90766 Evaluation of bleb characteristics after trabeculectomy and glaucoma implant surgery in rabbit
Shimazawa M
Ophthalmic Research 2021; 64: 68-76
90701 One-Year Efficacy and Safety Assessment of Ripasudil, a Rho Kinase Inhibitor, in an Addition to or Replacing Existing Treatment Regimens: A Retrospective Study
Anraku A; Tomita G
Journal of Ocular Pharmacology and Therapeutics 2020; 36: 512-521
90766 Evaluation of bleb characteristics after trabeculectomy and glaucoma implant surgery in rabbit
Otsuka T; Inagaki S; Kawase K; Hara H; Yamamoto T
Ophthalmic Research 2021; 64: 68-76

Issue 21-3

Change Issue


advertisement

Oculus